SCHEMBL1684757

SCHEMBL1684757

Fc1ccc(Nc2nccc(-c3cnc4ccccn34)n2)cc1

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 10/20 0.71
IGF1R P08069 2/20 0.71
PKM P14618 3/20 0.64
CDK4 P11802 3/20 0.60
CDK1 P06493 2/20 0.60
IRAK4 Q9NWZ3 2/20 0.56
MAPK8 P45983 3/20 0.55
MAPK9 P45984 2/20 0.55
FLT3 P36888 1/20 0.54
DYRK1A Q13627 1/20 0.54
CCNE1 P24864 1/20 0.52
MEN1 O00255 1/20 0.50
NPC1 O15118 1/20 0.50
LMNA P02545 1/20 0.50
MAPT P10636 1/20 0.50
ALOX12 P18054 1/20 0.50
MAPK1 P28482 1/20 0.50
RAB9A P51151 1/20 0.50
KMT2A Q03164 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17943211 0.90 CDK2 (0.77) CDK2IGF1RPKMCDK4CDK1
SCHEMBL27637599 0.88 CDK2 (0.78) CDK2IGF1RPKMCDK4CDK1
SCHEMBL1684897 0.87 CDK2 (0.77) CDK2IGF1RPKMCDK4CDK1
SCHEMBL29544603 0.87 CDK2 (0.60) CDK2IGF1RPKMCDK4CDK1
SCHEMBL28718947 0.87 CDK2 (0.60) CDK2IGF1RPKMCDK4CDK1
SCHEMBL1684661 0.85 CDK2 (0.67) CDK2IGF1RCDK4CDK1IRAK4
SCHEMBL1684809 0.85 CDK2 (0.67) CDK2IGF1RCDK4CDK1IRAK4
SCHEMBL27491478 0.85 CDK2 (0.76) CDK2IGF1RPKMCDK4CDK1
SCHEMBL23241872 0.84 CDK2 (0.72) CDK2IGF1RPKMCDK4CDK1
SCHEMBL7978513 0.84 CDK2 (0.69) CDK2IGF1RCDK4CDK1IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2306836-B1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2016-09-07 EP claimed
US-8680113-B2 BMI-1 protein expression modulators PTC THERAPEUTICS, INC. (US) 2014-03-25 US claimed
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2011-08-04 US claimed
EP-2306836-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC Therapeutics, Inc. (US) 2011-04-13 EP claimed
WO-2010002985-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2010-01-07 WO claimed
EP-3111956-B1 BMI 1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2019-05-08 EP disclosed
EP-3111956-A1 BMI 1 PROTEIN EXPRESSION MODULATORS PTC Therapeutics, Inc. (US) 2017-01-04 EP disclosed
EP-2306836-B1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2016-09-07 EP disclosed
US-8680113-B2 BMI-1 protein expression modulators PTC THERAPEUTICS, INC. (US) 2014-03-25 US disclosed
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS BMI1, CREBBP, BAZ2A CDK2 1442/4885IGF1R 1957/4885PKM 3941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.